Claire is currently a Partner in the Life Science team at Oxford Science Enterprises, an investment company that creates transformational businesses via a unique partnership with the University of Oxford, UK, the world’s #1 research university. Her focus is building and investing in novel therapeutics and therapeutic platforms across diverse therapy areas and modalities. She currently supports a number of OSE’s emerging companies incl. T-Cypher Bio, Nucleome, Alveogene and Orfonyx. Claire has spent the majority of her career in the global BioPharmaceutical industry at UCB Group, Sanofi-Genzyme and AstraZeneca where she worked in a variety of roles covering R&D strategy, licensing and corporate VC.